iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Rating of "Hold" by Brokerages

Key Points

• iTeos Therapeutics, Inc. has received a consensus rating of "Hold" from seven brokerage firms, with an average target price of $15.50.
• The company reported a quarterly earnings per share (EPS) of ($1.51), missing the consensus estimate by ($0.39).
• Recent insider selling included Director David Hallal offloading 38,228 shares and CEO Michel Detheux selling 43,883 shares, indicating a significant decrease in insider ownership.

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) has earned a consensus recommendation of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $15.50.

Several equities research analysts have issued reports on ITOS shares. Wedbush restated an "outperform" rating and set a $10.50 price objective (down from $12.00) on shares of iTeos Therapeutics in a report on Monday, July 21st. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Piper Sandler downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, July 21st. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Finally, Leerink Partners reiterated a "market perform" rating and issued a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th.

iTeos Therapeutics Stock Down 0.1%

ITOS stock opened at $10.20 on Friday. iTeos Therapeutics has a 52-week low of $4.80 and a 52-week high of $18.01. The stock's 50 day moving average is $10.13 and its two-hundred day moving average is $8.32. The company has a market capitalization of $450.94 million, a PE ratio of -2.18 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.39). As a group, sell-side analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current year.

Insider Buying and Selling

In other news, Director David Hallal sold 38,228 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total value of $391,454.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michel Detheux sold 43,883 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the sale, the chief executive officer owned 153,903 shares of the company's stock, valued at $1,542,108.06. This trade represents a 22.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 277,185 shares of company stock valued at $2,805,412 over the last quarter. Company insiders own 14.20% of the company's stock.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently made changes to their positions in ITOS. EcoR1 Capital LLC bought a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at approximately $106,569,000. BVF Inc. IL bought a new position in iTeos Therapeutics during the 4th quarter worth $17,856,000. RA Capital Management L.P. grew its stake in iTeos Therapeutics by 74.4% during the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock worth $21,785,000 after buying an additional 1,556,798 shares during the last quarter. Boxer Capital Management LLC bought a new position in iTeos Therapeutics during the 4th quarter worth $7,272,000. Finally, 683 Capital Management LLC grew its stake in iTeos Therapeutics by 90.6% during the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after buying an additional 831,883 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.